Cinpanemab in Parkinson’s Disease: Imaging and Fluid Biomarker Results from the Phase 2 SPARK Study
Objective: To evaluate the effects of cinpanemab on biomarkers in participants with Parkinson’s disease (PD). Background: SPARK (NCT03318523) was designed to evaluate the safety, pharmacokinetics,…Lateralized Tau Pathology in a Case of Lewy Body Dementia with Corticobasal Syndrome
Objective: To measure bilateral in vivo and postmortem tau pathology in a well-characterized patient presenting with corticobasal syndrome (CBS) due to underlying neocortical stage Lewy…α-synuclein and deficits of membrane trafficking in Parkinson’s Disease
Objective: Aim of the study is to understand the physical and functional relationships between the PD-associated protein α-synuclein and some of the Soluble N-ethylmaleimide-sensitive-factor Attachment…FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS
Objective: In the first-in-man clinical study of intermittent intraputamenal monthly infusions of CDNF in subjects with moderately advanced PD, we explored cerebrospinal fluid (CSF) biomarkers…Extensive volume increases sensitivity of alpha-synuclein accumulation in the gastrointestinal tract
Objective: This study aimed to verify whether evaluation of extensive tissue volume increases sensitivity of detecting alpha-synuclein (AS) pathology in the gastrointestinal (GI) tract in…Neurogenetic Traits Outline Vulnerability to Cortical Disruption in Parkinson’s Disease
Objective: In this study, we characterized the brain topological intersection between propagating connectivity networks in healthy controls (HC) and Parkinson’s disease (PD) participants and gene…Evaluating Engagement of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody to Physiological and Pathological Forms of Alpha-Synuclein for Phase 2 Dose Selection: A PBPK Modeling and Simulation Approach
Objective: To develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model to assist in the dose and dosing regimen selection of ABBV-0805 for Phase 2 studies. Background:…Elucidating multimodal endophenotypes of APOE-ε4 in α-synucleinopathies
Objective: To systematically identify phenotypes that consistently associate with the ε4-allele of apolipoprotein E (APOE-ε4) in α-synucleinopathies. Background: The APOE-ε4 presents an elevated risk not…A53T-SNCA-BAC transgenic mouse exhibits multiple prodromal symptoms of Parkinson’s disease: Gastrointestinal dysfunction, hyposmia and RBD-like behavior.
Objective: To develop biomarkers and disease-modifying therapies for Parkinson’s disease, an animal model that recapitulates the early phase of the disease is indispensable. The aim…Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody in Healthy Subjects
Objective: To evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of ABBV-0805 following administration of single ascending doses of ABBV-0805, administered as intravenous (IV) infusions…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 60
- Next Page »